Patient Safety Movement Foundation Announces Winners of 2021 Humanitarian and Lewis Blackman Awards
The Patient Safety Movement Foundation (PSMF), a global non-profit committed to achieving zero preventable patient deaths by 2030, announced the winners of its 2021 Humanitarian and Lewis Blackman awards at its 8th annual World Patient Safety, Science & Technology Summit (WPSSTS). President Bill Clinton, the 42nd President of the United States, was recognized with the Joe Kiani Humanitarian award, Javier Davila received the Beau Biden Humanitarian award and Jannicke Mellin-Olson was honored with the Steven Moreau Humanitarian award. The 2nd annual Lewis Blackman award was presented to Ingrid Bonilla.
“Achieving our mission of zero preventable patient deaths by 2030 relies on individuals coming together to create change,” said Michael Ramsay, MD, CEO of Patient Safety Movement Foundation. “We are proud to recognize all four of this year’s winners for their individual efforts, leadership and commitment to improving patient safety globally.”
The Humanitarian Awards recognize leaders who have made significant progress in the last year eliminating or raising awareness of preventable patient deaths. This year, recipients were honored across three categories – the Joe Kiani award, Beau Biden award and Steven Moreau award. The Joe Kiani award was named after the founder of the Patient Safety Movement Foundation and recognizes individuals who are committed to the foundation’s mission. The Beau Biden award was created in 2018 to honor Beau Biden, former attorney general of Delaware, member of the Army National Guard and late son of President Joe Biden, for his devotion to public service and the safety of others, especially children. The Steven Moreau award is presented annually to a hospital administrator who possesses a zeal for improving patient safety at their hospital. This year’s recipients included:
- President Bill Clinton, 42nd President of the United States, has been a long-standing supporter of patient safety. During his time in office, he was committed to expanding access to affordable, quality health care for all Americans. He received the first-ever Joe Kiani award for his continued support of the Patient Safety Movement Foundation and its goal to reach zero preventable medical deaths by 2030.
- Javier Davila, PSMF ambassador in Mexico, former medical director at the Mexican Social Security Institute and head of medical education, research and health public policy, was recognized with the Beau Biden award for his passion for public service and improving patient safety for others. Since joining PSMF, he has focused on promoting the culture of safety in Mexico and has helped build affiliations with many prestigious public and private hospitals, as well as establish relationships with numerous organizations to help further the mission.
- Jannicke Mellin-Olson, MD, DPH, has been a longtime patient safety advocate. Her passion for patient safety started during her residency at Trondheim University Hospital in Norway, where she worked on a number of patient safety initiatives. She received the Steven Moreau award for her continued efforts to spread the mission to stakeholders across Europe, as well as in her current clinical post at Baerum Hospital in Oslo, Norway.
The Lewis Blackman Leadership Award was established in 2020 to recognize active students or residents pursuing a career in healthcare who demonstrate exemplary leadership skills in patient safety that contribute to PSMF’s vision of eliminating preventable medical harm. It was designed in honor of Lewis Blackman, who died on November 6, 2000 at the age of 15, as a result of preventable medical harm in a healthcare setting with a poor culture of safety and inadequate training. Before his death, he was an outstanding student and his mother, Helen Haskell, has become an advocate for improving patient safety, especially through education.
- Ingrid Bonilla, fourth year medical student at Medical University of South Carolina, has demonstrated an early commitment and passion for improving patient safety. During her time in medical school, she has worked with noted patient safety champions in South Carolina on new criteria to prevent central line infections, collected data on COVID-19 to determine how it presents itself in children and how they should be treated and has also focused on improving communication between patients, families and providers.
The Patient Safety Movement Foundation launched the Humanitarian Awards in 2013 to recognize individuals whose work helps advance patient safety and the Lewis Blackman Award was created in 2019. To learn more about the awards and past winners, visit: https://patient.sm/LewisBlackman.
The full WPSSTS event is available to watch on demand for $20 through May 9, 2022 at: http://patient.sm/summit2022 or free after May 9 at: http://patient.sm/summitYT.
About the Patient Safety Movement Foundation: The Patient Safety Movement Foundation (PSMF), a global non-profit organization founded in 2012, is celebrating 10 years of bringing awareness and creating action to eliminate preventable medical errors. Some estimates predict that one in 12 patients are impacted by a preventable medical error, but that number could be even higher as there is no central database tracking these figures in most countries, including the U.S. Over the last decade, there had been major strides to improve patient safety, but the COVID-19 pandemic stressed the system and it proved not to be resilient and took a step backwards. PSMF has a vision to eliminate preventable patient harm and death across the globe by 2030 – and that starts with raising awareness of this critical issue. It unites patients, advocates, health workers, medical technology companies, government, employers and private payers in support of this cause. From its evidence-based best practice solutions (Actionable Patient Safety Solutions™) and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org, and follow PSMF on LinkedIn, Twitter, Instagram and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005501/en/
Contact information
Leslie Licano, Beyond Fifteen Communications, Inc.
psmf@beyondfifteen.com | (949) 733-8679 ext.101
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coulson Aviation Announces Launch of Boeing 767 VLAT Program22.12.2025 15:03:00 EET | Press release
Coulson Aviation USA has announced the launch of its Boeing 767 Very Large Airtanker (VLAT) program, marking a significant advancement in the evolution of aerial firefighting capability. The program is intended to provide a sustainable replacement for legacy VLAT platforms nearing the end of their operational service life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222917730/en/ A cross-sectional view of Coulson Aviation’s Boeing 767 Very Large Airtanker (VLAT) illustrates the integration of the RADS retardant delivery system and the next generation of high-capacity, sustainable aerial firefighting design. The recent grounding of the MD11 and DC10 fleets has highlighted a structural challenge for firefighting agencies worldwide. As older widebody aircraft are retired, the industry faces a significant reduction in high-capacity, large-scale retardant delivery capability. Coulson’s 767 VLAT is being developed to address
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
